September 2018 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016 and the 2017/18 Invitation to Tender, dated 2 November 2017.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Colchicine |
Tab 500 mcg, 100 tablet, bottle pack |
$10.08 |
$9.58 |
Colgout |
1 November 2018 |
1 February 2019 |
|
Ferrous fumarate |
Tab 200 mg (65 mg elemental), 100 tablet, blister pack |
$2.89 |
$3.09 |
Ferro-tab |
1 November 2018 |
1 February 2019 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Date of subsidy change |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Colchicine |
Tab 500 mcg, 100 tablet, bottle pack |
$10.08 |
$9.58 |
Colgout |
1% |
1 November 2018 |
1 January 2019 |
|
Doxorubicin hydrochloride1 |
Inj 2 mg per ml, 100 ml vial, 1 vial pack |
$46.00 |
$56.15 |
Doxorubicin Ebewe |
1% |
1 November 2018 |
1 January 2019 |
|
Ferrous fumarate |
Tab 200 mg (65 mg elemental), 100 tablet, blister pack |
$2.89 |
$3.09 |
Ferro-tab |
1% |
1 November 2018 |
1 January 2019 |
|
1 The price and subsidy of Doxorubicin hydrochloride inj 2 mg per ml, 100 ml vial in Section B of the Pharmaceutical Schedule will also be amended from 1 November 2018. The subsidy for doxorubicin hydrochloride inj 1 mg for ECP (Baxter) in Section B of the Pharmaceutical Schedule will change from $0.25 per 1 mg to $0.29 per 1 mg from 1 January 2019. |
|||||||
3. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Carboplatin1 |
Inj 10 mg per ml, 45 ml vial, 1 vial pack |
$32.59 |
$45.20 |
Carboplatin Ebewe |
1% |
1 April 2019 |
1 June 2019 |
DBL Carboplatin |
|
Linezolid |
Inj 2 mg per ml, 300 ml bottle, 1 solution for injection |
$1,650.00 |
$18.50 per 1 |
Linezolid Kabi |
1% |
1 December 2018 |
1 February 2019 |
Zyvox |
| 1 The price and subsidy of Carboplatin inj 10 mg per ml, 45 ml vial in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 April 2019. The subsidy for carboplatin inj 1 mg for ECP (Baxter) in Section B of the Pharmaceutical Schedule will change from $0.08 per 1 mg to $0.10 per 1 mg from 1 June 2019. | ||||||||
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2016/17 Invitation to Tender, dated 3 November 2016, and
- the 2017/18 Invitation to Tender, dated 2 November 2017.
2016/17 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Buprenorphine with naloxone |
Tab sublingual 2 mg with naloxone 0.5 mg |
|
Buprenorphine with naloxone |
Tab sublingual 8 mg with naloxone 2 mg |
|
Cetirizine hydrochloride |
Oral liq 1 mg per ml |
2017/18 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Benzoyl peroxide |
Soln/Gel 5% |
|
Carboplatin |
Inj 10 mg per ml, 15 ml |
|
Hydrocortisone butyrate |
Lipocream 0.1% (pack size 30 g or less) |
|
Hydrogen peroxide |
Soln 3% (10 vol) |
|
Imipenem with cilastatin |
Inj 500 mg with cilastatin 500 mg |
|
Oxaliplatin |
Inj 50 mg |
For products included in the 2016/17 and 2017/18 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.